Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014

Current HIV/AIDS Reports

Volumn 10, Issue 4, 2013, Pages 408-419

  Chastain, Cody A ^a   Naggie, Susanna ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Boceprevir; Daclatasvir; Faldaprevir; Hepatitis C; HIV; HIV HCV coinfection; Simeprevir; Sofosbuvir; Telaprevir

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; FALDAPREVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PROTEINASE INHIBITOR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG TARGETING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; LIVER CIRRHOSIS; MIXED INFECTION; MORTALITY; NONHUMAN; RISK BENEFIT ANALYSIS; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COINFECTION; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84891160700     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-013-0182-8     Document Type: Article

References (97)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-42.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128.
3. Ly KN, Xing JJ, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271-8.
4. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43(1):66-72.
5. Zalesak M, Francis K, Gedeon A, Gillis J, Hvidsten K, Kidder P, et al. Current and future disease progression of the chronic HCV Population in the United States. PLoS ONE. 2013;8(5):e63959. doi: 10.1371/journal.pone.0063959.
6. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831-7.
7. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30 Suppl 1:S77-84.
8. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632-41.
9. Butt AA, Khan UA, Shaikh OS, McMahon D, Dorey-Stein Z, Tsevat J, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials. 2009;10(1):25-32.
10. Butt AA, McGinnis K, Skanderson M, Justice AC. A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans. AIDS Research and Human Retroviruses. 2011;27(9):973-9.
11. Thein H-H, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979-91.
12. De Ledinghen V, Barreiro P, Foucher J, Labarga P, Castera L, Vispo ME, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepatitis. 2008;15(6):427-33.
13. Fierer DS, Dieterich DT, Fiel MI, Branch AD, Marks KM, Fusco DN, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis. 2013;56(7):1038-43.
14. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24(10):1537-48.
15. Hernando V, Perez-Cachafeiro S, Lewden C, Gonzalez J, Segura F, Oteo JA, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol. 2012;57(4):743-51.
16. Berenguer J, Alejos B, Hernando V, Viciana P, Salavert M, Santos I, et al. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS. 2012;26(17):2241-6.
17. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. YJCGH. 2011;9(6):509-16.
18. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93.
19. Berenguer J, Álvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407-13.
20. Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012;308(4):370-8. This prospective cohort noted fewer liver-related clinical events in HIV-HCV coinfected patients on antiretroviral therapy. No events were detected in a subset of 51 patients treated with HCV therapy who achieved SVR.
21. Mira JA, Rivero-Juarez A, Lopez-Cortes LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56(11):1646-53. In this prospective cohort of HIV-HCV coinfected patients with cirrhosis, 43 of 166 patients achieved SVR after treatment with pegylated interferon and ribavirin. Patients who achieved an SVR had a significantly lower rate of liver decompensation and overall mortality.
22. Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials. 2012;13(3):142-52.
23. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20(18):2361-9.
24. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annual Rev Med. 2008;59:473-85.
25. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 1996;125(8):634-9.
26. Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol. 2012;84(11):1744-50.
27. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007;132(5):1979-98.
28. Naggie S, Patel K, McHutchison J. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J Antimicrob Chemother. 2010;65(10):2063-9.
29. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Med. 2013;19(7):837-49.
30. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451-9.
31. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-50.
32. Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18(13):F27-36.
33. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839-48.
34. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-16.
35. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014-24.
36. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-28.
37. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86-96. This phase 2 trial demonstrated the clinical efficacy of telaprevir in HIV-HCV coinfected patients. HIV coinfected, HCV treatment naïve patients treated with telaprevir plus P/R achieved an SVR of 74% while patients treated with placebo plus P/R achieved an SVR of 45%.
38. Rodriguez-Torres M. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient. Current Opin Inf Dis. 2013;26(1):50-7.
39. Van Heeswijk R, Garg V, Boogaerts G, Vandebosch A, Luo D, Witek J, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September 17-20, 2011. [Abstract A1-1738a].
40. Van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011), Boston, MA, February 27 - March 2, 2011. [Abstract 119].
41. Kakuda T, Leopold L, Nijs S, et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomized, two-way crossover trial. 13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, Spain, April 16-18, 2012. [Abstract O18].
42. Johnson M, Borland J, Chen S-J, Savina P, Wynne B, Piscatelli S. Dolutegravir, boceprevir, telaprevir PK: the effect of boceprevir and telaprevir on dolutegravir pharmacokinetics, in healthy adult subjects. 14th International Workshop on Clinical Phamacology of HIV Therapy, Amsterdam, the Netherlands, April 22-24, 2013. [Abstract O16].
43. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206.
44. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17.
45. Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. YJCGH. 2013;11(1):81-7.
46. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Inf Dis. 2013;13(7):597-605. This phase 2 trial demonstrated the clinical efficacy of boceprevir in HIV-HCV coinfected patients. HIV coinfected, HCV treatment naïve patients treated with boceprevir plus P/R achieved an SVR of 63% while patients treated with placebo plus P/R achieved an SVR of 29%.
47. Kassera C, Hughes E, Treitel M, et al. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions. 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011), Boston, MA, February 27 - March 2, 2011. [Abstract 118].
48. Hulskotte E, Feng H, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), Seattle, WA, March 5-8, 2012. [Abstract 771LB].
49. Garraffo R, Poizot-Martin I, Piroth L, Pol TLS, Bellissant E, Teicher E, et al. Pharmacokinetic (PK) interactions between boceprevir (BOC) and atazanavir/r (ATV/r) or raltegravir (RAL) in HIV/HCV coinfected patients (pts). 14th International Workshop on Clinical Pharmacology on HIV Therapy, Amsterdam, the Netherlands, April 22-24, 2013. [Abstract O-15].
50. De Kanter C, Blonk M, Colbers A, et al. Influence of the HCV protease inhibitor boceprevir on the pharmacokinetics of the HIV integrase inhibitor raltegravir. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), Seattle, WA, March 5-8, 2012. [Abstract 772LB].
51. Hammond KP, Wolfe P, Burton Jr JR, Predhomme JA, Ellis CM, Ray ML, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr. 2013;62(1):67-73.
52. Vourvahis M, Plotka A, Kantaridis C, Fang A, Heera J. Maraviroc, boceprevir, telaprevir PK in healthy volunteers: the effect of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers. 14th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, the Netherlands, April 22-24, 2013. [Abstract O17].
53. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Accessed at: http://aidsinfo.nih.gov/ contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Last accessed: September 19, 2013.
54. European Medicines Agency. Victrelis: EPAR - Product Information. Annex I: Summary of Product Characteristics. Accessed at: www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/002332/WC500109786.pdf. Last accessed: September 19, 2013.
55. Hezode C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders: first results of the French early access program (ANRS CO20-CUPIC). J Hepatol. 2012;56:S4.
56. Fried M, Reddy K, Di Bisceglie A, Jensen D, Jacobson I, Sulkowski MS, et al. HCV-TARGET: a longitudinal, observational study of North American patients with chronic hepatitis C treated with boceprevir or telaprevir. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, the Netherlands, April 24-28, 2013. [Abstract 818].
57. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Inf Dis. 2013;13(5):401-8.
58. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87. The NEUTRINO trial, reported in concert with the FISSION trial in this article, demonstrated the efficacy of sofosbuvir in combination with P/R. This regimen may become part of the new standard of care for HCV genotype 1 infection.
59. Kowdley K, Hassanein T, Gane E, Hyland R, Ma J, Symonds W, et al. Sofosbuvir safety and tolerability in 741 patients treated for up to 24 weeks. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, the Netherlands, April 24-28, 2013. [Abstract 842].
60. Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A, Shen G, Symonds B, McHutchison J, et al. Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naïve genotype 1-4 HCV-infected patients who are coinfected with HIV. IDWeek 2013 (Infectious Diseases Society of America), San Francisco, CA, October 2-6, 2013. [Abstract 714]. This recent report highlights the effectiveness of sofosbuvir in combination with P/R in HIV-HCV coinfected patients. This regimen may become part of the new standard of care for HIV-HCV coinfected patients.
61. Jacobson I, Ghalib R, Rodriguez-Torres M, Younossi Z, Corregidor A, Sulkowski M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington, DC, November 1-5, 2013. [Abstract LB-3].
62. Sulkowski M, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chonic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, the Netherlands, April 24-28, 2013. [Abstract 1417].
63. Sulkowski M, Gardiner D, Rodriguez-Torres M, Reddy K, Hassanein T, Jacobson I, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucelotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCV GT 1, 2, or 3. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA, November 9-12, 2012. [Abstract LB-2].
64. Osinusi A, Meissner EG, Lee Y-J, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804.
65. Sulkowski M, Rodriguez-Torres M, Lalezari J, Fessel W, Mounzer K, Shuhart M, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington, DC, November 1-5, 2013. [Abstract 66]. This study is one of the first to evaluate an all-oral DAA regimen in HIV-HCV coinfected patients. This regimen may become part of the new standard of care for HIV-HCV coinfected patients.
66. Kirby B, Mathias A, Rossi S, et al. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals Atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. 63rd Annual Meeting of the American Association of the Study of Liver Diseases (AASLD), Boston, MA, November 9-13, 2012. [Abstract 1877].
67. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. YGAST. 2010;138(3):913-21.
68. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012;56(6):1247-53.
69. Jacobson I, Dore G, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, the Netherlands, April 24-28, 2013. [Abstract 1525].
70. Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, the Netherlands, April 24-28, 2013. [Abstract 1413].
71. Zeuzem S, Berg T, Gane E, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final SVR24 results of the ASPIRE trial. 47th Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, April 18-22, 2012. [Abstract 2].
72. Lawitz E, Forns X, Zeuzem S, Gane E, Bronowicki J-P, Andreone P, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial. Digestive Disease Week 2013, Orlando, FL, May 18-21, 2013. [Abstract 869b].
73. FDA Antiviral Drugs Advisory Committee Meeting Briefing Information. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AntiviralDrugsAdvisoryCommittee/ucm371875.htm. Last accessed 8 Nov 2013.
74. Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir (TMC435) plus pegylated interferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: primary analysis of the TMC435-C212 study. 14th European AIDS Conference (EACS 2013), Brussels, Belgium, October 16-19, 2013. [Abstract PS9/5]. These results highlight the use of simeprevir in HIV-HCV coinfected patients. This study supports the use of simeprevir in HIV-HCV coinfected patients.
75. Ouwerkerk-Mahadevan S, Sekar V, Peeters M, Beumont-Mauviel M. The pharmacokintic interactions of HCV protease inhibitor TMC435 with rilpivirine, tenofovir, efavirenz or raltegravir in healthy volunteers. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), Seattle, WA, March 5-8, 2012. [Abstract 49].
76. White P, Llinas-Brunet M, Amad M, et al. Preclinical characterization of non covalent HCV NS3/4A protease inhibitor BI 201335. J Hepatol. 2010;52 Suppl 1:S302.
77. Jensen D, Asselah T, Dieterich D, Foster G, Sulkowski M, Zeuzem S, et al. A pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C genotype-1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington, DC, November 1-5, 2013. [Abstract 1088].
78. Jacobson I, Asselah T, Ferenci P, Foster G, Jensen D, Negro F, et al. STARTVerso3: A randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington, DC, November 1-5, 2013. [Abstract 1100].
79. Rockstroh J, Nelson M, Soriano V, Arasteh K, Guardiola J, Bhagani S, et al. STARTVerso 4 phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington, DC, November 1-5, 2013. [Abstract 1099]. These interim results from this phase 2 trial demonstrate another DAA regimen in HIV-HCV coinfected patients. Early results reveal high end of treatment responses that vary regarding to genotype and prior treatment experience.
80. Sabo J, Kort J, Haschke M, et al. Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the hepaitis C virus protease inhibitor faldaprevir in healthy volunteers. 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), Atlanta, GA, March 3-6, 2013. [Abstract 35].
81. Lok A, Gardiner D, Hezode C, et al. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA, November 9-13, 2012. [Abstract 79]
82. Sulkowski M, Gardiner D, Rodriguez-Torres M, Reddy K, Hassanein T, Jacobson I, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCV GT 1, 2, or 3. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA, November 9-12, 2012. [Abstract LB-2].
83. Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antiviral Ther. Epub August 20, 2013. DOI: 10.3851/IMP2674. Last accessed: October 7, 2013.
84. Kowdley K, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT-450/R, ABT-267, ABT-333 ± ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, the Netherlands, April 24-28, 2013. [Abstract 3]
85. Thompson A, Hans S, Shiffman M, et al. GS-5885 (ledipasvir) + GS-9451 + peginterferon and ribavirin (PR) for six or twelve weeks achieves high SVR12 rates in treatment-naïve genotype 1 IL28B CC patients. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, the Netherlands, April 24-28, 2013. [Abstract 64].
86. Everson G, Di Bisceglie A, Vierling J, et al. Combination of the NS5A inhibitor, GS5885, the NS3 protease inhibitor, GS-9451, and pegylated interferon plus ribavirin in treatment experienced patients with genotype 1 hepatitis C infection. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, the Netherlands, April 24-28, 2013. [Abstract 13].
87. Gane E, Stedman CA, Hyland RH et al. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin: the ELECTRON trial. 64th Annual Meeting of the American Society for the Study of Liver Diseases (AASLD), Washington, DC, Nov 1-5, 2013. [Abstract 73].
88. Lawitz E, Poordad F, Hyland RH, et al. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin resulted in >95 % sustained virologic response in patients with HCV genotype 1, including patients with cirrhosis: the LONESTAR trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, Nov 1-5, 2013. [Abstract 215].
89. Everson G, Sims K, Thuluvath PJ, et al. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection. 64th Annual Meeting of the American Society for the Study of Liver Diseases (AASLD), Washington, DC, November 1-5, 2013. [Abstract LB-1].
90. Zeuzem S, Soriano V, Asselah T, Bronowicki J-P, Lohse AW, Müllhaupt B, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med. 2013;369(7):630-9.
91. Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim expands investigation of interferon-free hepatitis C treatment regimens to reach more patient types through Presidio Pharmaceuticals clinical collaboration. Accessed at: us.boehringer-ingelheim.com/news-events/press-release-archive/2013/09-10-13- boehringer-iongelheim-expands-investigation-interferon-free-hepatitis-c- treatment-regimens-reach-more-patient-types-presidio-pharmaceuticals-clinical- collaboration.html. Last accessed: September 19, 2013.
92. Sherman KE. Managing adverse effects and complications in completing treatment for hepatitis C virus infection. Top Antivir Med. 2012;20(4):125-8.
93. Jacobson IM, Kowdley KV, Kwo PY. Anemia management in the era of triple combination therapy for chronic HCV. Gastroenterol Hepatol. 2012;8(9; Suppl 6):1-16.
94. Sulkowski M, Roberts S, Afdhal N, et al. Ribavirin dose modification in treatment-naïve and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies. J Hepatol. 2011;54 Suppl 1:S195.
95. Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2011;23(12):1192-9.
96. Payer BA, Reiberger T, Breitenecker F, Aichelburg MC, Schuster C, Heil PM, et al. The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN + RBV. J Infection. 2012;65(2):142-9.
97. Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int. 2013;33:30-4.